Eric A Klein

List of Publications by Year in Descending Order

119 papers	12,534 citations	48 h-index	111 g-index
120 ext. papers	14,679 ext. citations	6.9 avg, IF	5.56 L-index

#	Paper	IF	Citations
119	Multicancer early detection.. *Clinical Chemistry and Laboratory Medicine*, **2022**,	5.9	
118	The Promise of Multicancer Early Detection. Comment on Pons-Belda et al. Can Circulating Tumor DNA Support a Successful Screening Test for Early Cancer Detection? The Grail Paradigm. Diagnostics 2021, 11, 2171. *Diagnostics*, **2022**, 12, 1243	3.8	2
117	Validating the Association of Adverse Pathology with Distant Metastasis and Prostate Cancer Mortality 20-Years After Radical Prostatectomy. *Urologic Oncology: Seminars and Original Investigations*, **2021**, 40, 104.e1-104.e1	2.8	0
116	Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancer. *Journal of Clinical Investigation*, **2021**, 131,	15.9	5
115	Prognostic Significance of Blood-Based Multi-cancer Detection in Plasma Cell-Free DNA. *Clinical Cancer Research*, **2021**, 27, 4221-4229	12.9	18
114	The PATHFINDER Study: Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test into Clinical Practice. *Cancers*, **2021**, 13,	6.6	11
113	Prostate cancer in young men represents a distinct clinical phenotype: gene expression signature to predict early metastases. *Journal of Translational Genetics and Genomics*, **2021**, 5, 50-61	1.7	0
112	Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. *Nature Genetics*, **2021**, 53, 65-75	36.3	62
111	GPS Assay Association With Long-Term Cancer Outcomes: Twenty-Year Risk of Distant Metastasis and Prostate Cancer-Specific Mortality. *JCO Precision Oncology*, **2021**, 5,	3.6	1
110	Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. *Annals of Oncology*, **2020**, 31, 745-759	10.3	303
109	Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline. *Journal of Clinical Oncology*, **2020**, 38, 1474-1494	2.2	66
108	Development and Validation of a Genomic Tool to Predict Seminal Vesicle Invasion in Adenocarcinoma of the Prostate.. *JCO Precision Oncology*, **2020**, 4, 1228-1238	3.6	0
107	Surgical management of high-risk, localized prostate cancer. *Nature Reviews Urology*, **2020**, 17, 679-690	5.5	9
106	Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance. *Prostate Cancer and Prostatic Diseases*, **2020**, 23, 136-143	6.2	16
105	Older Age at Diagnosis and Initial Disease Volume Predict Grade Reclassification Risk on Confirmatory Biopsy in Patients Considered for Active Surveillance. *Urology*, **2019**, 130, 106-112	1.6	2
104	Influence of the facility caseload on the subsequent survival of men with localized prostate cancer undergoing radical prostatectomy. *Cancer*, **2019**, 125, 3853-3863	6.4	3
103	Genome-wide cell-free DNA (cfDNA) methylation signatures and effect on tissue of origin (TOO) performance.. *Journal of Clinical Oncology*, **2019**, 37, 3049-3049	2.2	12

102	The Circulating Cell-free Genome Atlas (CCGA) Study: Follow-up (F/U) on non-cancer participants with cancer-like cell-free DNA signals.. *Journal of Clinical Oncology*, **2019**, 37, 5574-5574	2.2	4
101	Outcomes of very high-risk prostate cancer after radical prostatectomy: Validation study from 3 centers. *Cancer*, **2019**, 125, 391-397	6.4	20
100	Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer. *JAMA - Journal of the American Medical Association*, **2018**, 319, 896-905	27.4	171
99	Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer. *European Urology*, **2018**, 73, 524-532	10.2	35
98	Genomic Scores are Independent of Disease Volume in Men with Favorable Risk Prostate Cancer: Implications for Choosing Men for Active Surveillance. *Journal of Urology*, **2018**, 199, 438-444	2.5	8
97	The scientific impact and value of large, NCI-sponsored randomized phase III cancer chemoprevention trials. *Cancer Epidemiology*, **2018**, 55, 117-122	2.8	3
96	The 17-Gene Genomic Prostate Score Assay Predicts Outcome After Radical Prostatectomy Independent of PTEN Status. *Urology*, **2018**, 121, 132-138	1.6	5
95	Prostate cancer prevention **2018**, 145-170		
94	Development of a comprehensive cell-free DNA (cfDNA) assay for early detection of multiple tumor types: The Circulating Cell-free Genome Atlas (CCGA) study.. *Journal of Clinical Oncology*, **2018**, 36, 12021-12021	2.2	37
93	Tissue-Based Markers for Risk Prediction. *Current Clinical Urology*, **2018**, 121-133		
92	Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer. *Journal of Clinical Oncology*, **2018**, 36, 581-590	2.2	107
91	Evaluation of a 24-gene signature for prognosis of metastatic events and prostate cancer-specific mortality. *BJU International*, **2017**, 119, 961-967	5.6	5
90	Clinical and molecular rationale to retain the cancer descriptor for Gleason score 6 disease. *Nature Reviews Urology*, **2017**, 14, 59-64	5.5	2
89	Prognostic Significance of a Negative Confirmatory Biopsy on Reclassification Among Men on Active Surveillance. *Urology*, **2017**, 107, 184-189	1.6	6
88	Intermediate-Term Outcomes for Men with Very Low/Low and Intermediate/High Risk Prostate Cancer Managed by Active Surveillance. *Journal of Urology*, **2017**, 198, 591-599	2.5	22
87	Access to high-volume surgeons and the opportunity cost of performing radical prostatectomy by low-volume providers. *Urologic Oncology: Seminars and Original Investigations*, **2017**, 35, 459.e15-459.e24	2.8	2
86	Low PCA3 expression is a marker of poor differentiation in localized prostate tumors: exploratory analysis from 12,076 patients. *Oncotarget*, **2017**, 8, 50804-50813	3.3	27
85	A Prospective Study of Chronic Inflammation in Benign Prostate Tissue and Risk of Prostate Cancer: Linked PCPT and SELECT Cohorts. *Cancer Epidemiology Biomarkers and Prevention*, **2017**, 26, 1549-1557	4	41

84	Molecular Analysis of Low Grade Prostate Cancer Using a Genomic Classifier of Metastatic Potential. *Journal of Urology*, **2017**, 197, 122-128	2.5	29
83	Two Novel Susceptibility Loci for Prostate Cancer in Men of African Ancestry. *Journal of the National Cancer Institute*, **2017**, 109,	9.7	38
82	Therapy-induced developmental reprogramming of prostate cancer cells and acquired therapy resistance. *Oncotarget*, **2017**, 8, 18949-18967	3.3	38
81	A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score. *European Urology*, **2016**, 69, 428-35	10.2	762
80	Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation. *Nature Communications*, **2016**, 7, 10979	17.4	37
79	Decipher Genomic Classifier Measured on Prostate Biopsy Predicts Metastasis Risk. *Urology*, **2016**, 90, 148-52	1.6	116
78	Gene expression in normal-appearing tissue adjacent to prostate cancers are predictive of clinical outcome: evidence for a biologically meaningful field effect. *Oncotarget*, **2016**, 7, 33855-65	3.3	14
77	Molecular markers in urologic oncology: prostate cancer. *Current Opinion in Urology*, **2016**, 26, 225-30	2.8	5
76	Opportunities and challenges in incorporating ancillary studies into a cancer prevention randomized clinical trial. *Trials*, **2016**, 17, 400	2.8	1
75	Selenium- or Vitamin E-Related Gene Variants, Interaction with Supplementation, and Risk of High-Grade Prostate Cancer in SELECT. *Cancer Epidemiology Biomarkers and Prevention*, **2016**, 25, 1050-1058	4	39
74	Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy. *European Urology*, **2015**, 67, 1160-1167	10.2	133
73	Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes. *European Urology*, **2015**, 68, 555-67	10.2	100
72	Integration of multiethnic fine-mapping and genomic annotation to prioritize candidate functional SNPs at prostate cancer susceptibility regions. *Human Molecular Genetics*, **2015**, 24, 5603-18	5.6	35
71	Novel Biomarker Signature That May Predict Aggressive Disease in African American Men With Prostate Cancer. *Journal of Clinical Oncology*, **2015**, 33, 2789-96	2.2	99
70	Prostate cancer: MR-TRUS fusion biopsy--defining a new standard. *Nature Reviews Clinical Oncology*, **2015**, 12, 253-4	19.4	5
69	Age-related cataract in men in the selenium and vitamin e cancer prevention trial eye endpoints study: a randomized clinical trial. *JAMA Ophthalmology*, **2015**, 133, 17-24	3.9	30
68	Applying precision medicine to the active surveillance of prostate cancer. *Cancer*, **2015**, 121, 3403-11	6.4	18
67	Methylome-wide Sequencing Detects DNA Hypermethylation Distinguishing Indolent from Aggressive Prostate Cancer. *Cell Reports*, **2015**, 13, 2135-46	10.6	26

66	Are biochemical recurrence outcomes similar after radical prostatectomy and radiation therapy? Analysis of prostate cancer-specific mortality by nomogram-predicted risks of biochemical recurrence. *European Urology*, **2015**, 67, 204-9	10.2	34
65	A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy. *European Urology*, **2015**, 67, 778-86	10.2	126
64	Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer risk. *Journal of the National Cancer Institute*, **2014**, 106, djt456	9.7	184
63	Do margins matter? The influence of positive surgical margins on prostate cancer-specific mortality. *European Urology*, **2014**, 65, 675-80	10.2	61
62	Leveraging population admixture to characterize the heritability of complex traits. *Nature Genetics*, **2014**, 46, 1356-62	36.3	45
61	Reply to Yuri Tolkach, Markus Kuczyk, Florian Imkamp's letter to the editor re: Eric A. Klein, Matthew R. Cooperberg, Cristina Magi-Galluzzi, et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur Urol 2014;66:550-60. *European Urology*, **2014**, 66, e117-8	10.2	6
60	Plasma vitamin D and prostate cancer risk: results from the Selenium and Vitamin E Cancer Prevention Trial. *Cancer Epidemiology Biomarkers and Prevention*, **2014**, 23, 1494-504	4	78
59	A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. *Nature Genetics*, **2014**, 46, 1103-9	36.3	331
58	Plasma tocopherols and risk of prostate cancer in the Selenium and Vitamin E Cancer Prevention Trial (SELECT). *Cancer Prevention Research*, **2014**, 7, 886-95	3.2	52
57	A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. *European Urology*, **2014**, 66, 550-60	10.2	421
56	Optimal definition of biochemical recurrence after radical prostatectomy depends on pathologic risk factors: identifying candidates for early salvage therapy. *European Urology*, **2014**, 66, 204-10	10.2	37
55	A functional variant in NKX3.1 associated with prostate cancer risk in the Selenium and Vitamin E Cancer Prevention Trial (SELECT). *Cancer Prevention Research*, **2014**, 7, 950-7	3.2	21
54	Is there a role for body mass index in the assessment of prostate cancer risk on biopsy?. *Journal of Urology*, **2014**, 192, 1094-9	2.5	12
53	Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. *Journal of the National Cancer Institute*, **2013**, 105, 1132-41	9.7	223
52	Moving a randomized clinical trial into an observational cohort. *Clinical Trials*, **2013**, 10, 131-42	2.2	17
51	Analytical validation of the Oncotype DX prostate cancer assay - a clinical RT-PCR assay optimized for prostate needle biopsies. *BMC Genomics*, **2013**, 14, 690	4.5	226
50	Changing Landscape of Prostate Cancer Favoring Low-Risk Prostate Cancer: Implications for Active Surveillance Versus Focal Therapy **2013**, 17-36		
49	Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT. *Journal of Urology*, **2012**, 187, 2005-10	2.5	33

48	In-depth investigation of archival and prospectively collected samples reveals no evidence for XMRV infection in prostate cancer. *PLoS ONE*, **2012**, 7, e44954	3.7	33
47	Chemoprevention of prostate cancer: an updated view. *World Journal of Urology*, **2012**, 30, 189-94	4	17
46	Absence of XMRV and closely related viruses in primary prostate cancer tissues used to derive the XMRV-infected cell line 22Rv1. *PLoS ONE*, **2012**, 7, e36072	3.7	13
45	No biological evidence of XMRV in blood or prostatic fluid from prostate cancer patients. *PLoS ONE* , **2012**, 7, e36073	3.7	8
44	Epidemiology, Etiology, and Prevention of Prostate Cancer **2012**, 2704-2725.e7		5
43	Avoiding androgen deprivation therapy in men with high-risk prostate cancer: the role of radical prostatectomy as initial treatment. *Urology*, **2011**, 77, 946-50	1.6	16
42	Predicting 15-year prostate cancer specific mortality after radical prostatectomy. *Journal of Urology* , **2011**, 185, 869-75	2.5	463
41	In vivo hypermutation of xenotropic murine leukemia virus-related virus DNA in peripheral blood mononuclear cells of rhesus macaque by APOBEC3 proteins. *Virology*, **2011**, 421, 28-33	3.6	5
40	Surgery confounds biology: the predictive value of stage-, grade- and prostate-specific antigen for recurrence after radical prostatectomy as a function of surgeon experience. *International Journal of Cancer*, **2011**, 128, 1697-702	7.5	4
39	Phase III trial of selenium to prevent prostate cancer in men with high-grade prostatic intraepithelial neoplasia: SWOG S9917. *Cancer Prevention Research*, **2011**, 4, 1761-9	3.2	93
38	Infection, viral dissemination, and antibody responses of rhesus macaques exposed to the human gammaretrovirus XMRV. *Journal of Virology*, **2011**, 85, 4547-57	6.6	37
37	Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). *JAMA - Journal of the American Medical Association*, **2011**, 306, 1549-56	27.4	1150
36	Sexual Transmission of XMRV: A Potential Infection Route. *Advances in Virology*, **2011**, 2011, 965689	1.9	5
35	XMRV Discovery and Prostate Cancer-Related Research. *Advances in Virology*, **2011**, 2011, 432837	1.9	3
34	Association of Mycoplasma hominis infection with prostate cancer. *Oncotarget*, **2011**, 2, 289-97	3.3	81
33	The human retrovirus XMRV in prostate cancer and chronic fatigue syndrome. *Nature Reviews Urology*, **2010**, 7, 392-402	5.5	51
32	Variations among experienced surgeons in cancer control after open radical prostatectomy. *Journal of Urology*, **2010**, 183, 977-82	2.5	47
31	Chemoprevention of prostate cancer. *Urologic Clinics of North America*, **2010**, 37, 11-21, Table of Contents	2.9	11

30	Five year biochemical recurrence free survival for intermediate risk prostate cancer after radical prostatectomy, external beam radiation therapy or permanent seed implantation. *Urology*, **2010**, 76, 1251-7	1.6	49
29	Fellowship training as a modifier of the surgical learning curve. *Academic Medicine*, **2010**, 85, 863-8	3.9	25
28	Characterization of antibodies elicited by XMRV infection and development of immunoassays useful for epidemiologic studies. *Retrovirology*, **2010**, 7, 68	3.6	33
27	The Epstein criteria predict for organ-confined but not insignificant disease and a high likelihood of cure at radical prostatectomy. *European Urology*, **2010**, 58, 90-5	10.2	58
26	Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. *Journal of Clinical Oncology*, **2009**, 27, 4300-5	2.2	351
25	Selenium and vitamin E: interesting biology and dashed hope. *Journal of the National Cancer Institute*, **2009**, 101, 283-5	9.7	16
24	Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). *JAMA - Journal of the American Medical Association*, **2009**, 301, 39-51	27.4	1518
23	Fibrils of prostatic acid phosphatase fragments boost infections with XMRV (xenotropic murine leukemia virus-related virus), a human retrovirus associated with prostate cancer. *Journal of Virology*, **2009**, 83, 6995-7003	6.6	66
22	Risk-adjusted hazard rates of biochemical recurrence for prostate cancer patients after radical prostatectomy. *European Urology*, **2009**, 55, 412-19	10.2	16
21	Preoperative and postoperative nomograms incorporating surgeon experience for clinically localized prostate cancer. *Cancer*, **2009**, 115, 1005-10	6.4	62
20	Risk factors for prostate cancer. *Nature Reviews Urology*, **2009**, 6, 87-95		77
19	Chemoprevention of prostate cancer. *Journal of Urology*, **2009**, 182, 499-507; discussion 508	2.5	51
18	Location, extent and number of positive surgical margins do not improve accuracy of predicting prostate cancer recurrence after radical prostatectomy. *Journal of Urology*, **2009**, 182, 1357-63	2.5	150
17	Effects of pathologic stage on the learning curve for radical prostatectomy: evidence that recurrence in organ-confined cancer is largely related to inadequate surgical technique. *European Urology*, **2008**, 53, 960-6	10.2	85
16	Validation of pretreatment nomograms for predicting indolent prostate cancer: efficacy in contemporary urological practice. *Journal of Urology*, **2008**, 180, 150-4; discussion 154	2.5	48
15	Surgeon experience is strongly associated with biochemical recurrence after radical prostatectomy for all preoperative risk categories. *Journal of Urology*, **2008**, 179, 2212-6; discussion 2216-7	2.5	111
14	Pathological aggressiveness of prostatic carcinomas related to RNASEL R462Q allelic variants. *Journal of Urology*, **2008**, 179, 1344-8	2.5	14
13	Integration site preference of xenotropic murine leukemia virus-related virus, a new human retrovirus associated with prostate cancer. *Journal of Virology*, **2008**, 82, 9964-77	6.6	85

12	Inflammation, infection, and prostate cancer. *Current Opinion in Urology*, **2008**, 18, 315-9	2.8	75
11	Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy. *European Urology*, **2007**, 51, 1175-84	10.2	172
10	Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. *Journal of Clinical Oncology*, **2007**, 25, 2035-41	2.2	694
9	The surgical learning curve for prostate cancer control after radical prostatectomy. *Journal of the National Cancer Institute*, **2007**, 99, 1171-7	9.7	309
8	An infectious retrovirus susceptible to an IFN antiviral pathway from human prostate tumors. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 1655-60	11.5	177
7	Identification of a novel Gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. *PLoS Pathogens*, **2006**, 2, e25	7.6	443
6	Local recurrence of prostate cancer in rectal submucosa after transrectal needle biopsy and radical prostatectomy. *Urology*, **2005**, 66, 881	1.6	35
5	Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). *Journal of the National Cancer Institute*, **2005**, 97, 94-102	9.7	275
4	Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. *JAMA - Journal of the American Medical Association*, **2004**, 291, 1325-32	27.4	503
3	Effects of RNase L mutations associated with prostate cancer on apoptosis induced by 2′,5′oligoadenylates. *Cancer Research*, **2003**, 63, 6795-801	10.1	118
2	RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. *Nature Genetics*, **2002**, 32, 581-3	36.3	241
1	Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. *Journal of Clinical Oncology*, **2002**, 20, 3376-85	2.2	197